Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG7N3W
|
|||
| Drug Name |
Retatrutide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 3 | [1] | |
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric inhibitory polypeptide receptor (GIPR) | Target Info | Agonist | [2] |
| Glucagon receptor (GCGR) | Target Info | Agonist | [2] | |
| Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| Glucagon signaling in metabolic regulation | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05882045) A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease. U.S.National Institutes of Health. | |||
| REF 2 | Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.